MX2022007844A - Tratamiento de una lesion cerebral traumatica moderada. - Google Patents

Tratamiento de una lesion cerebral traumatica moderada.

Info

Publication number
MX2022007844A
MX2022007844A MX2022007844A MX2022007844A MX2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A MX 2022007844 A MX2022007844 A MX 2022007844A
Authority
MX
Mexico
Prior art keywords
treatment
brain injury
traumatic brain
mild traumatic
mtbi
Prior art date
Application number
MX2022007844A
Other languages
English (en)
Spanish (es)
Inventor
Vishal Bansal
Kartik Shah
Michael Wyand
Original Assignee
Oxeia Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxeia Biopharmaceuticals Inc filed Critical Oxeia Biopharmaceuticals Inc
Publication of MX2022007844A publication Critical patent/MX2022007844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022007844A 2019-12-23 2020-12-22 Tratamiento de una lesion cerebral traumatica moderada. MX2022007844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962953130P 2019-12-23 2019-12-23
PCT/US2020/066703 WO2021133844A1 (en) 2019-12-23 2020-12-22 Treatment of mild traumatic brain injury

Publications (1)

Publication Number Publication Date
MX2022007844A true MX2022007844A (es) 2022-09-07

Family

ID=76575665

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007844A MX2022007844A (es) 2019-12-23 2020-12-22 Tratamiento de una lesion cerebral traumatica moderada.

Country Status (11)

Country Link
US (1) US20230031262A1 (cg-RX-API-DMAC10.html)
EP (1) EP4081238A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023508250A (cg-RX-API-DMAC10.html)
KR (1) KR20220122691A (cg-RX-API-DMAC10.html)
CN (1) CN114980915A (cg-RX-API-DMAC10.html)
AU (1) AU2020412765A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022012365A2 (cg-RX-API-DMAC10.html)
CA (1) CA3165738A1 (cg-RX-API-DMAC10.html)
IL (1) IL294156A (cg-RX-API-DMAC10.html)
MX (1) MX2022007844A (cg-RX-API-DMAC10.html)
WO (1) WO2021133844A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370804A1 (en) * 2021-01-22 2022-11-24 The Regents Of The University Of Colorado, A Body Corporate Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders
CN113723530B (zh) * 2021-09-02 2022-03-25 中国科学院自动化研究所 基于视频分析和电子心理沙盘的智能心理评估系统
US20260077018A1 (en) * 2022-09-07 2026-03-19 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6545697B2 (ja) * 2013-11-15 2019-07-17 ニューラル・アナリティクス・インコーポレーテッド 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること
US9119832B2 (en) * 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CA2961889A1 (en) * 2014-08-19 2016-02-25 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
US20180028617A1 (en) * 2015-02-19 2018-02-01 The Regents Of The University Of California Methods of treating mild brain injury and post-traumatic stress disorder
WO2016144978A1 (en) * 2015-03-09 2016-09-15 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Also Published As

Publication number Publication date
US20230031262A1 (en) 2023-02-02
CN114980915A (zh) 2022-08-30
BR112022012365A2 (pt) 2022-08-30
JP2023508250A (ja) 2023-03-01
IL294156A (en) 2022-08-01
KR20220122691A (ko) 2022-09-02
CA3165738A1 (en) 2021-07-01
AU2020412765A1 (en) 2022-07-14
WO2021133844A1 (en) 2021-07-01
EP4081238A1 (en) 2022-11-02
EP4081238A4 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
WO2018022664A8 (en) Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseases
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
EP4079373A4 (en) THERAPEUTIC ULTRASOUND GENERATING DEVICE AND HANDPIECE FOR ULTRASOUND TREATMENT THEREOF
NZ751690A (en) Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
MX2009012188A (es) Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
WO2015165948A3 (en) Compositions for the treatment of diabetic neuropathies
MX2019012086A (es) Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal.
EP3590338A3 (en) Medical treatments based on anamorelin
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
WO2019157527A3 (en) Methods related to parkinson's disease and synucleinopathies
PL3969009T3 (pl) Beta-1,3'-galaktozylolaktoza do leczenia chorób związanych z funkcją bariery jelitowej
EA201691567A1 (ru) Способы лечения легких травм головного мозга
WO2017106175A3 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
BR112022012365A2 (pt) Tratamento de lesão cerebral traumática leve
GB202011522D0 (en) Neuromodulation for the treatment of circulatory system diseases
GB201013785D0 (en) Treatment
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
WO2018111795A3 (en) Use of sgc stimulators for the treatment of esophageal motility disorders